NovoCure (NVCR) Gains from Investment Securities (2014 - 2026)

NovoCure has disclosed Gains from Investment Securities across 13 years of filings, most recently posting -$2.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$2.0 million, up 20.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.5 million (up 51.82% YoY), and the FY2025 annual result was $30.7 million, up 30.73% from the prior year.
• Gains from Investment Securities came in at -$2.0 million for Q1 2026 at NovoCure, down from $37.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $37.2 million in Q4 2025 to a low of -$11.0 million in Q4 2022.
• The 5-year median for Gains from Investment Securities is $2.9 million (2024), against an average of $6.1 million.
• Across the five-year window, Gains from Investment Securities soared 1160.56% in 2022 and sank 240.42% in 2023, its largest moves.
• NovoCure's Gains from Investment Securities stood at -$11.0 million in 2022, then soared by 296.09% to $21.6 million in 2023, then jumped by 45.2% to $31.4 million in 2024, then climbed by 18.2% to $37.2 million in 2025, then tumbled by 105.5% to -$2.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$2.0 million (Q1 2026), $37.2 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.